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Worldwide trends in diabetes since 1980: a pooled analysis of 
751 population-based studies with 4·4 million participants
NCD Risk Factor Collaboration (NCD-RisC)*
Summary
Background One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-
standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how 
likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth 
and ageing, are aﬀ ecting the number of adults with diabetes. 
Methods We pooled data from population-based studies that had collected data on diabetes through measurement of 
its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence—deﬁ ned as fasting 
plasma glucose of 7·0 mmol/L or higher, or history of diagnosis with diabetes, or use of insulin or oral hypoglycaemic 
drugs—in 200 countries and territories in 21 regions, by sex and from 1980 to 2014. We also calculated the posterior 
probability of meeting the global diabetes target if post-2000 trends continue.
Findings We used data from 751 studies including 4 372 000 adults from 146 of the 200 countries we make estimates for. 
Global age-standardised diabetes prevalence increased from 4·3% (95% credible interval 2·4–7·0) in 1980 to 9·0% 
(7·2–11·1) in 2014 in men, and from 5·0% (2·9–7·9) to 7·9% (6·4–9·7) in women. The number of adults with diabetes 
in the world increased from 108 million in 1980 to 422 million in 2014 (28·5% due to the rise in prevalence, 39·7% due 
to population growth and ageing, and 31·8% due to interaction of these two factors). Age-standardised adult diabetes 
prevalence in 2014 was lowest in northwestern Europe, and highest in Polynesia and Micronesia, at nearly 25%, followed 
by Melanesia and the Middle East and north Africa. Between 1980 and 2014 there was little change in age-standardised 
diabetes prevalence in adult women in continental western Europe, although crude prevalence rose because of ageing 
of the population. By contrast, age-standardised adult prevalence rose by 15 percentage points in men and women in 
Polynesia and Micronesia. In 2014, American Samoa had the highest national prevalence of diabetes (>30% in both 
sexes), with age-standardised adult prevalence also higher than 25% in some other islands in Polynesia and Micronesia. 
If post-2000 trends continue, the probability of meeting the global target of halting the rise in the prevalence of diabetes 
by 2025 at the 2010 level worldwide is lower than 1% for men and is 1% for women. Only nine countries for men and 
29 countries for women, mostly in western Europe, have a 50% or higher probability of meeting the global target.
Interpretation Since 1980, age-standardised diabetes prevalence in adults has increased, or at best remained 
unchanged, in every country. Together with population growth and ageing, this rise has led to a near quadrupling of 
the number of adults with diabetes worldwide. The burden of diabetes, both in terms of prevalence and number of 
adults aﬀ ected, has increased faster in low-income and middle-income countries than in high-income countries.
Funding Wellcome Trust.
Copyright © NCD Risk Factor Collaboration. Open Access article distributed under the terms of CC BY.
Introduction
Diabetes is an important cause of mortality, morbidity, 
and health-system costs in the world.1,2 Therefore, there is 
an urgent need to implement population-based inter-
ventions that prevent diabetes, enhance its early detection, 
and use lifestyle and pharmacological interventions to 
prevent or delay its progression to complications. To 
motivate such actions, one of the global targets set after 
the 2011 UN High-Level Meeting on Non-Communicable 
Diseases (NCDs) is to halt, by 2025, the rise in the age-
standardised adult prevalence of diabetes at its 2010 
levels.3 Valid and consistent estimates of diabetes 
prevalence over time are needed to evaluate the eﬀ ect of 
interventions, compare trends in diﬀ erent countries, and 
measure progress towards the agreed target.
A previous study estimated trends in mean fasting 
plasma glucose from 1980 to 2008 and reported diabetes 
prevalence, but only as a secondary outcome and estimated 
based on mean fasting plasma glucose.4 The International 
Diabetes Federation (IDF) periodically reports diabetes 
prevalence,5,6 but does not analyse trends; uses some 
sources that are based solely on self-reported diabetes; and 
does not fully account for diﬀ erences in diabetes 
deﬁ nitions in diﬀ erent data sources,7 even though diabetes 
prevalence varies depending on whether it is deﬁ ned based 
on fasting plasma glucose, 2 h plasma glucose in an oral 
glucose tolerance test (2hOGTT), or haemoglobin A1c 
(HbA1c).8 Furthermore, it is not known how trends in 
prevalence, together with population growth and ageing, 
have aﬀ ected the number of adults with diabetes. Our aim 
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was to estimate worldwide trends in the prevalence and 
number of adults with diabetes. We also estimated the 
probability of achieving the global diabetes target.
Methods
Study design and deﬁ nitions
We estimated trends in diabetes prevalence from 1980 to 
2014, in 200 countries and territories organised into 
21 regions, mostly on the basis of geography and national 
income (appendix pp 11–12). The exception was a region 
consisting of high-income English-speaking countries 
because cardiometabolic risk factors, especially body-mass 
index (BMI), an important risk factor for diabetes, have 
similar trends in these countries, which can be distinct 
from other countries in their geographical region. As the 
primary outcome, diabetes was deﬁ ned as fasting plasma 
glucose of 7·0 mmol/L or higher, history of diagnosis with 
diabetes, or use of insulin or oral hypoglycaemic drugs. 
This deﬁ nition of diabetes is used in the Global Monitoring 
Framework for NCDs;3 it also relies more directly on data 
from population-based health-examination surveys, 
which, for logistical reasons, are more likely to measure 
fasting plasma glucose than 2hOGTT. Our analysis 
covered men and women aged 18 years or older, consistent 
with the Global Monitoring Framework for NCDs.3
Our study had three stages, each described in detail below 
and in the appendix (pp 2–8). First, we identi ﬁ ed, accessed, 
and reanalysed population-based health-examination 
surveys that had measured at least one diabetes biomarker. 
We then converted diabetes prevalence in sources that had 
deﬁ ned diabetes through 2hOGTT or HbA1c or used a cutoﬀ  
other than 7·0 mmol/L for fasting plasma glucose, to a 
corresponding prevalence based on the primary outcome as 
deﬁ ned above. Finally, we applied a statistical model to the 
pooled data to estimate trends for all countries and years.
Data sources
We included data sources that were representative of a 
national, subnational, or community population and that 
had measured at least one of the following diabetes 
biomarkers: fasting plasma glucose, 2hOGTT, and HbA1c. 
We did not use data from sources that relied entirely on 
self-reported history of diagnosis because this approach 
would miss undiagnosed diabetes, which forms a 
substantial share of all people with diabetes, especially in 
communities with little access to health care.9–11 Our 
methods for identifying and accessing data sources are 
described in the appendix (pp 2–6).
History of diabetes diagnosis was established with 
survey-speciﬁ c questions, such as “have you ever been 
told by a doctor or other health professional that you have 
diabetes?” or the combination of “do you now have, or 
have you ever had diabetes?” and “were you told by a 
doctor that you had diabetes?” Similarly, the use of 
diabetes drugs was established with survey-speciﬁ c 
questions, such as “are you currently taking medication 
for diabetes or high blood sugar?” or the combination of 
“do you currently inject insulin for diabetes?” and “are 
you currently taking any medicines, tablets, or pills for 
diabetes?” Some surveys also veriﬁ ed medications with 
use of visual inspection or medical records, or had used 
these approaches to establish the use of diabetes drugs.
Conversion to a consistent deﬁ nition of diabetes
9% of our data were from sources that had reported the 
prevalence of diabetes based on 2hOGTT or HbA1c but not 
Research in context
Evidence before this study
We searched MEDLINE (via PubMed) for articles published 
between Jan 1, 1950, and Dec 11, 2013, with the search terms 
(“Blood Glucose”[MAJR] OR “Diabetes Mellitus”[MAJR:NoExp] 
OR “Diabetes Mellitus, Type 2”[MAJR:NoExp] OR “Diabetes 
Mellitus, Type 1”[MAJR:NoExp] OR “Prediabetic state”[MAJR] 
OR “Hyperglycemia”[MAJR] OR “Hemoglobin A, 
Glycosylated”[MAJR]) AND (“Humans”[Mesh]). Articles were 
screened according to the inclusion and exclusion criteria 
described in the appendix (pp 2–6).
A few studies have reported diabetes trends in one or a few 
countries. A previous study reported diabetes prevalence 
trends to 2008 as a secondary outcome, which was estimated 
from mean fasting plasma glucose. This study was done 
before the global target on diabetes was agreed, hence there 
are no recent data. The International Diabetes Federation 
periodically reports diabetes prevalence but does not analyse 
trends, uses some sources that are only based on self-reported 
diabetes, and does not fully account for diﬀ erences in diabetes 
deﬁ nitions in diﬀ erent data sources.
Added value of this study
This study provides the lengthiest and most complete 
estimates of trends in adult diabetes prevalence worldwide. 
We achieved this level of detail by reanalysing and pooling 
hundreds of population-based sources with actual 
measurements of at least one diabetes biomarker and 
systematically converting all data sources to a common 
deﬁ nition of diabetes. We also systematically projected recent 
trends into the future, and assessed the probability of achieving 
the global diabetes target.
Implications of all the available evidence
Since 1980, age-standardised diabetes prevalence in adults 
increased or at best remained unchanged in every country. 
The burden of diabetes, in terms of both prevalence and 
number of adults aﬀ ected, has increased faster in low-income 
and middle-income countries than in high-income countries. 
If post-2000 trends continue, the probability of meeting the 
global diabetes target is lower than 1% for men and is 1% for 
women worldwide. 
See Online for appendix
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fasting plasma glucose. Another 29% of data were from a 
previous global pooling study4 or extracted from published 
reports and papers, and had used fasting plasma glucose 
but reported only mean plasma con centrations or a 
prevalence based on a cutoﬀ  other than 7·0 mmol/L (eg, 
≥7·8 mmol/L). To correct for in com parability of 
deﬁ nitions of diabetes, we used regressions that converted 
prevalence from these sources to our primary outcome. 
The dependent variable in each of these regressions, 
which are described in detail elsewhere8 and presented in 
the appendix (pp 7–8 and 30–79), was the primary outcome 
(prevalence of fasting plasma glucose ≥7·0 mmol/L or 
history of diabetes diagnosis or use of diabetes drugs), and 
the main independent variable was a prevalence based on 
the deﬁ nitions in at least one study that did not report the 
primary outcome but had some form of data on diabetes 
and glycaemia. The coeﬃ  cients of these regressions were 
estimated from data sources with individual-level data, 
which could be used to calculate prevalence with both 
deﬁ nitions. Details of conversion (or cross-walking) 
regressions, and their speciﬁ cation and coeﬃ  cients, are 
presented in the appendix (pp 30–79). Datapoints based 
on fewer than 25 people were excluded. All regressions 
included terms for age, sex, country, income (natural 
logarithm of per-capita gross domestic product adjusted 
for purchasing power and inﬂ ation), and the year of study. 
When we used more than 400 datapoints to estimate the 
regression coeﬃ  cients, the regressions also included 
regional random eﬀ ects. Finally, we included interaction 
terms in the regressions if the interaction terms provided 
a better ﬁ t to the data as determined by the Bayesian 
Information Criterion.
Statistical analysis
The statistical model used to estimate diabetes prevalence 
by country, year, age, and sex is described in detail in a 
statistical paper and in related substantive papers.12–14 In 
summary, we used a hierarchical probit model in which 
diabetes levels and trends in countries were nested in 
regional levels and trends, which were in turn nested in 
those of super-regions and worldwide. In this structure, 
estimates of diabetes levels and trends for each country 
and year were informed by the country’s own data, if 
available, and by data from other years in the same country 
and in other countries, especially those in the same 
region, with data for similar time periods. The hierarchical 
structure borrows information to a greater degree when 
data are non-existent or weakly informative (eg, because 
they have a small sample size or are not national), and to a 
lesser extent in data-rich countries and regions.
The model incorporated non-linear time trends and 
age patterns, allowing the age pattern of diabetes to vary 
across populations such that the rise in prevalence with 
age would be steeper where diabetes prevalence is 
higher.15 The model accounted for the fact that prevalence 
in subnational and community studies might 
systematically diﬀ er from nationally representative 
surveys, and also tends to have larger variation relative to 
the true values than national studies do. These features 
were implemented by including data-driven ﬁ xed-eﬀ ect 
and random-eﬀ ect terms for subnational and community 
data. The ﬁ xed eﬀ ects adjust for systematic diﬀ erences 
between sub national or community studies and national 
studies. The random eﬀ ects allow national data to have 
larger inﬂ uence on the estimates than subnational or 
community data with similar sample sizes. The model 
also accounted for rural–urban diﬀ erences in diabetes 
prevalence, through the use of data-driven ﬁ xed eﬀ ects 
for rural-only and urban-only studies. These rural and 
urban eﬀ ects were weighted by the diﬀ erence between 
study-level and country-level urbanisation. The statistical 
model also included country-level covariates that help 
predict diabetes prevalence, including average number of 
years of education, proportion of national population 
living in urban areas, a summary measure of availability 
of diﬀ erent food types for human consumption, and age-
standardised adult mean BMI.16 The covariate on food 
availability was constructed from the food balance sheets 
of the Food and Agriculture Organization of the UN, 
with use of principal component analysis. Details of the 
variables, data, and methods are provided elsewhere.13,17
We ﬁ tted this Bayesian model with the Markov chain 
Monte Carlo (MCMC) algorithm. Convergence was 
monitored and 5000 post-burn-in samples were obtained 
from the posterior distribution of model parameters, 
which were then used to obtain the posterior distributions 
of diabetes prevalence. The reported credible intervals 
(CrI) represent the 2·5–97·5 percentiles of the posterior 
distributions.
We report the posterior probability that an estimated 
increase or decrease represents a truly increasing or 
decreasing trend. Posterior probability would be 0·50 in 
a country or region in which an increase is statistically 
indistinguishable from a decrease; a larger posterior 
probability indicates more certainty in a change in 
prevalence. Additionally, we calculated the posterior 
probability of meeting the global target of no increase in 
diabetes prevalence if post-2000 trends continue. All 
analyses were done separately by sex. We used the WHO 
standard population for age standardisation.
We examined how well our model estimates diabetes 
prevalence in countries and years without data by 
withholding some of the data from the model and 
calculating the diﬀ erences between the held-out data 
and the estimates—ie, the error in estimates 
(appendix pp 9–10). This validation test shows that our 
model performed very well; the median errors were close 
to zero globally, and the median absolute errors were 
small (appendix pp 80–84).
Role of funding source
The funder of the study had no role in study design, 
data collection, analysis, interpretation, or writing of 
the report. Country and Regional Data Group 
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members, BZ, JB, and MDC had full access to the data 
in the study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for 
publication.
Results
We used data from 751 population-based measurement 
surveys and studies, which included 4 372 000 participants 
aged 18 years or older. The studies covered 146 (73%) of 
the 200 countries and territories for which estimates 
were made (appendix pp 97–98). These 146 countries 
contained 90% of the world’s adult population in 2014. 
Regionally, the average number of data sources per 
country ranged from less than one in central Africa to 
24 in the high-income Asia Paciﬁ c region. 21 (39%) of the 
54 countries without data were in sub-Saharan Africa, 
11 (20%) in the Caribbean, seven (13%) in central Europe, 
four (7%) in central Asia, and the remaining 11 (20%) in 
other regions. Nearly a third of surveys and studies (242) 
were from years before 2000, and the other two-thirds 
(509) for 2000 and later.
From 1980 to 2014, worldwide age-standardised adult 
diabetes prevalence increased from 4·3% (95% CrI 
2·4–7·0) to 9·0% (7·2–11·1) in men (ﬁ gure 1) and from 
5·0% (2·9–7·9) to 7·9% (6·4–9·7) in women (ﬁ gure 2); 
the posterior probabilities that these were true increases 
were 0·994 and 0·954, respectively. Over these years, 
crude adult prevalence increased from 3·6% (2·0–5·9) to 
8·8% (7·0–10·8) in men, and from 4·7% (2·7–7·4) to 
8·2% (6·6–9·9) in women (ﬁ gures 1, 2).
Age-standardised diabetes prevalence in women in 
2014 was lowest in northwestern and south western 
Europe, which each had a prevalence of less than 5% 
(ﬁ gure 2). The lowest prevalence in adult men was also 
in northwestern Europe, at 5·8% (95% CrI 3·6–8·7). 
Crude adult prevalence in northwestern Europe was 
5·9% (3·8–8·6) for women and 7·9% (5·1–11·5) for 
men in 2014. At the other extreme, age-standardised 
diabetes prevalence was higher than 20% in adult men 
and women in Polynesia and Micronesia, and around 
15% in Melanesia and in the Middle East and 
north Africa.
Over the 35 years of analysis, there was almost no 
change in age-standardised diabetes prevalence in 
women in northwestern and southwestern Europe, 
and only a small non-signiﬁ cant increase in central 
and eastern Europe (ﬁ gure 2). Adult men in 
northwestern Europe also had a smaller rise in 
prevalence than did other regions (ﬁ gure 1). By 
contrast, age-standardised prevalence in Polynesia and 
Micronesia rose by 15·0 (95% CrI 5·5–25·9) percentage 
points in adult men (posterior probability >0·999) and 
by 14·9 (4·5–26·2) percentage points in adult women 
(posterior probability 0·998). Crude adult prevalence 
increased more than age-standardised prevalence in 
regions that had substantial ageing—eg, in high-
income regions.
In 1980, age-standardised adult diabetes prevalence 
was lower than 3% in men in 32 countries and in women 
in 23 countries (ﬁ gures 3, 4). In the same year, age-
standardised prevalence was higher than 12% in adult 
men and women in a few islands in Polynesia and 
Micronesia and women in Kuwait, reaching 25% in men 
and women in Nauru. By 2014, women in only one 
country had an age-standardised adult prevalence lower 
than 3% and women in only nine countries had one 
lower than 4%, with the lowest prevalence estimated in 
some countries in northwestern Europe such as 
Switzerland, Austria, Denmark, Belgium, and the 
Netherlands (ﬁ gure 4). In the same year, age-standardised 
prevalence in adult men was higher than 4% in every 
country (ﬁ gure 3); the lowest estimated prevalences were 
in the same northwestern European countries as those 
for women and in a few countries in east Africa and 
southeast Asia. At the other extreme, age-standardised 
adult diabetes prevalence in 2014 was 31% (95% CrI 
19–44) in men and 33% (21–47) in women in American 
Samoa, and was also higher than 25% in men and 
women in some other islands in Polynesia and 
Micronesia (ﬁ gures 3, 4; appendix pp 85–94).
No country had a statistically signiﬁ cant decrease in 
diabetes prevalence from 1980 to 2014 (ﬁ gure 5), although 
the relative increase over these 35 years was lower than 
20% in nine countries for men, mostly in northwestern 
Europe, and in 39 countries for women. Over the same 
period, age-standardised adult prevalence of diabetes at 
least doubled for men in 120 countries and for women in 
87 countries, with a posterior probability of 0·887 or 
higher. The largest absolute increases in age-standardised 
adult prevalence were in Oceania, exceeding 
15 percentage points in some countries, followed by the 
Middle East and north Africa (ﬁ gure 5).
Worldwide, if post-2000 trends continue, the 
probability of meeting the global diabetes target for 
men is lower than 1%; for women it is 1%. Only nine 
countries, mostly in northwestern Europe, had a 50% 
or higher probability of meeting the global target for 
men, as did 29 countries for women (ﬁ gure 6). Rather, 
if post-2000 trends continue, age-standardised 
prevalence of diabetes in 2025 will be 12·8% (95% CrI 
8·3–19·6) in men and 10·4% (7·1–15·1) in women. The 
number of adults with diabetes will surpass 700 million.
The number of adults with diabetes in the world 
increased from 108 million in 1980, to 422 million in 2014 
(ﬁ gure 7). East Asia and south Asia had the largest rises of 
absolute numbers, and had the largest number of people 
with diabetes in 2014: 106 million and 86 million, 
respectively. 39·7% (n=124·8 million) of the rise in the 
number of people with diabetes was due to population 
growth and ageing, 28·5% (n=89·7 million) due to the 
rise in age-speciﬁ c prevalences, and the remaining 31·8% 
(n=99·9 million) due to the interaction of the two—ie, an 
older and larger population with higher age-speciﬁ c 
prevalences (ﬁ gure 7).
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Figure 1: Trends in age-standardised and crude prevalence of diabetes for men by region
The lines (solid for age-standardised and dashed for crude) show the posterior mean estimates; the shaded area shows the 95% credible intervals for age-standardised prevalence. For trends and numerical 
results by country see appendix pp 85–94, 103–170.
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Figure 2: Trends in age-standardised and crude prevalence of diabetes for women by region
The lines (solid for age-standardised and dashed for crude) show the posterior mean estimates; the shaded area shows the 95% credible intervals for age-standardised prevalence. For trends and numerical 
results by country see appendix pp 85–94, 103–170.
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Figure 3 : Age-standardised prevalence of diabetes in adult men by country in 1980 and 2014
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Figure 4: Age-standardised prevalence of diabetes in adult women by country in 1980 and 2014
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Half of adults with diabetes in 2014 lived in ﬁ ve 
countries: China, India, the USA, Brazil, and Indonesia 
(ﬁ gure 8). These countries also accounted for one half of 
the world’s adult population in 2014. Although the top 
three countries on this list remained unchanged from 
1980 to 2014, the global share of adults with diabetes who 
live in China and India increased, by contrast with the 
USA, where the share decreased. The changes in the 
share of adults with diabetes from India and the USA 
might be partly because of the changes in their shares. 
However, the share of the adult population of China 
remained virtually unchanged, while its share of the 
adult population with diabetes increased. Low-income 
and middle-income countries, including Indonesia, 
Pakistan, Mexico, and Egypt, replaced European 
countries, including Germany, Ukraine, Italy, and the 
UK, on the list of the top ten countries with most adults 
with diabetes (ﬁ gure 8).
Discussion
We used population-based data to document the global 
diabetes epidemic since 1980. Over this period, 
age-standardised diabetes prevalence in adults increased 
or at best remained unchanged in every country. It more 
than doubled in men and increased by 60% in women 
worldwide, shifting from an excess prevalence in women 
in 1980, to a higher male prevalence in 2014.18,19 This rise 
in prevalence has been compounded by population 
growth and ageing, nearly quadrupling the number 
of adults with diabetes over these 35 years. The burden of 
diabetes, both in terms of prevalence and number of 
adults with diabetes, increased at a greater rate 
in low-income and middle-income countries than 
in high-income countries. The highest national 
prevalences—generally those in Oceania, and the Middle 
East and north Africa—are now ﬁ ve to ten times greater 
than the lowest prevalences, which are in some western 
European countries.
Our estimates of diabetes prevalence for 2013 for the 
world as a whole are similar to those by the IDF for the 
same year,5,6 but there were diﬀ erences between our 
estimates and those from the IDF in some countries and 
regions. In particular, we estimated a higher age-
standardised prevalence of diabetes in most countries in 
the Middle East and north Africa than the IDF. The IDF 
does not estimate trends, hence we could not compare 
trend estimates. Our ﬁ nding that diabetes prevalence 
was low in much of Asia and sub-Saharan Africa in the 
1980s and 1990s is consistent with other studies that 
found low prevalences in these regions in those 
decades.20,21 Our ﬁ nding that diabetes prevalence did not 
increase in continental western Europe (especially in 
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Figure 6: Probability of achieving the target of halting the rise of diabetes in adults by 2025 at its 2010 levels by sex and country if post-2000 trends continue
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northwestern Europe) is also consistent with reports 
from Sweden,22 Germany,23 and Switzerland24 that covered 
a subset of our analysis years. Similarly, our estimated 
increases for high-income English-speaking countries 
are consistent with studies that had analysed repeated 
population-based surveys in the USA25 and the UK.26,27 A 
meta-analysis of 15 studies in Japan reported no increase 
in diabetes prevalence,28 as observed in our analysis. 
Several recent reports have also documented similar 
increases in diabetes prevalence to those observed in our 
analysis in China,29,30 India,31–34 Iran,35 Turkey,36 and Saudi 
Arabia.37 Finally, our ﬁ nding of the slower rise in diabetes 
prevalence in women compared with men is consistent 
with historical data in a few high-income countries.18,19
The larger rise in diabetes prevalence in low-income and 
middle-income countries than in high-income countries, 
and the mostly ﬂ at trends in Europe (especially in 
northwestern Europe), might be caused by several factors. 
First, adiposity, which is an important risk factor for 
diabetes, has increased substantially more, and is now 
higher, in many low-income and middle-income countries 
than in continental Europe and high-income Asia Paciﬁ c 
countries, especially in women.16 Second, regional 
diﬀ erences in diabetes could be due in part to diﬀ erences 
in genetic susceptibility or phenotypic variations arising 
from inadequate fetal and childhood nutrition and growth; 
earlier onset of β-cell dysfunction might be one 
diﬀ erentiating characteristic of Asian populations 
compared with European populations.38–42 Third, better-
resourced health systems in Europe and other high-
income countries might identify people at high risk of 
diabetes at an earlier stage, and use lifestyle and dietary 
modiﬁ cation or drugs to prevent or delay its onset.43–45 At 
the moment, information on the proportion of people 
with, or at risk of, diabetes who are diagnosed and receive 
treatment is limited to a few countries. Consistent 
information on diagnosis and treatment coverage will 
become increasingly important as universal health 
coverage becomes a central theme of global health eﬀ orts, 
and should be a focus of future analyses. Finally, in 
addition to total caloric intake and adiposity, dietary 
composition and physical activity might aﬀ ect diabetes risk 
and contribute to diﬀ erences in regional trends.46 These 
and other potential reasons for the divergent trends in 
diabetes prevalence should be investigated. Furthermore, 
the shift in diabetes burden from women towards men 
might be due to men having higher prevalences of some 
risk factors for diabetes, such as smoking, or being at risk 
of diabetes at lower BMI levels than are women.18,19
The strengths of our study include its scope of making 
consistent and comparable estimates of trends in diabetes 
prevalence and of the probabilities of meeting the global 
diabetes target. We used an unprecedented amount of 
population-based data, which came from countries in 
which 90% of the global adult population lives. We used 
only data from studies that had measured a diabetes 
biomarker to avoid bias in self-reported data. Data were 
analysed according to a common protocol, and the 
characteristics and quality of data sources were rigorously 
veriﬁ ed through repeated checks by Collaborating Group 
members from each country. We pooled data using a 
statistical model that took into account the epidemiological 
features of diabetes, including non-linear time trends and 
age associations, and used all available data while giving 
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more weight to national data than to subnational and 
community sources.
Despite our extensive eﬀ orts to identify and access 
worldwide population-based data, some countries had no 
or few data sources, especially those in sub-Saharan 
Africa, the Caribbean, central Asia, and central Europe. 
Estimates for these countries relied mostly or entirely on 
the statistical model, which shares information across 
countries and regions through its hierarchy and through 
predictive covariates. The absence or scarcity of data is 
reﬂ ected in wider uncertainty intervals of our estimates 
for these countries and regions (ﬁ gures 1, 2; appendix 
pp 103–170). Diabetes was reported using a deﬁ nition 
other than our primary outcome in some data sources, 
either because fasting plasma glucose was not measured 
or because individual-level data could not be accessed. To 
overcome this issue, we systematically used the reported 
metrics to estimate our primary outcome; the cross-
walking regressions used for this purpose had good 
predictive accuracy. The share of studies that used a 
portable device (instead of laboratory analysis) for 
measuring diabetes biomarkers has increased over time. 
We do not expect the rise in the use of portable devices to 
aﬀ ect the estimated levels and trends because their 
higher use in population-based research is partly due to 
increasing similarity between their measurements and 
those in laboratory-based tests,47,48 facilitated by more 
advanced technologies and better standardisation. 
Further, although our primary outcome is consistent 
with the NCD Global Monitoring Framework, diabetes 
prevalence based on fasting plasma glucose alone is 
lower than that based on the combination of fasting 
plasma glucose and 2hOGTT.8 Age-standardised adult 
diabetes prevalence would be 10·0% (95% CrI 8·0–12·5) 
for men and 8·8% (7·2–10·7) for women, worldwide, if 
we applied the cross-walking regression (similar to those 
in appendix pp 34–79) to convert our estimates to 
prevalence of diabetes deﬁ ned as fasting plasma glucose 
of 7·0 mmol/L or higher, or 2hOGTT of 11·1 mmol/L or 
higher, or history of diagnosis with diabetes or use of 
insulin or oral hypoglycaemic drugs. Finally, the survey 
data did not separate type 1 and type 2 diabetes because 
distinguishing between these disorders is diﬃ  cult in 
adults.49–51 However, most (85–95%) cases of diabetes in 
adults are type 2,50,52 so the observed rise in diabetes 
prevalence in adults is quite likely due to increases in 
type 2 diabetes. 
Diabetes and its macrovascular and microvascular 
complications account for more than 2 million deaths 
every year,1 and are the seventh leading cause of disability 
worldwide.53 Diabetes is also a risk factor for tuberculosis, 
another disease with large burden in low-income and 
middle-income countries.54 Diabetes and its compli-
cations impose substantial economic costs on patients, 
their families, health systems, and national economies 
because of direct costs of treatment and loss of work and 
wages.2 On the basis of estimates for the number of 
people with diabetes in 2014 in this study, and cost 
estimates from a systematic review,2 the direct annual 
cost of diabetes in the world is Intl$825 billion, with 
China ($170 billion), the USA ($105 billion), India 
($73 billion), and Japan ($37 billion) having the largest 
2·4 (2·2)9 Italy
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4·7 (4·4)5 Japan
20·4 (18·9)1 China
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Figure 8: Ten countries with the largest number of adults with diabetes in 1980 and 2014
Colours for each country indicate its region.
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costs. Nearly 60% of the global costs are borne by low-
income and middle-income countries, where substantial 
parts of treatment costs are paid out-of-pocket,2 which 
aﬀ ects treatment utilisation and adherence and leads to 
ﬁ nancial hardship for patients and their families.
Glucose reduction with lifestyle modiﬁ cation and 
drugs in people with diabetes, especially if started early, 
can delay progression to microvascular complications.55–57 
Although evidence is mixed from trials on the 
macrovascular beneﬁ ts of intensive glucose lowering,55,58–60 
long-term glycaemic control and lowering blood pressure 
and serum cholesterol also reduce the risk of adverse 
cardiovascular outcomes.61,62 However, the eﬀ ectiveness 
of these interventions at the population level has been 
slight, both because many diabetes cases remain 
undiagnosed9–11 and because adherence to treatment is 
typically lower in general populations than in those 
enrolled in clinical trials.63–65
Eﬀ orts to reduce the global health and economic 
burden of diabetes should emphasise prevention of 
diabetes or delaying its onset, through enhancing healthy 
behaviours and diets at the population level, and early 
detection and management of high-risk individuals. 
There has been little success in preventing obesity,16 the 
most important risk factor for diabetes, at the population 
level although the global target on obesity could engender 
new eﬀ orts and policy innovations. As these policies are 
implemented, identifying people at high risk of 
diabetes—especially those with impaired glucose 
tolerance—through the primary care system, using 
advice and support to induce and maintain lifestyle 
change, possibly together with drugs such as metformin, 
might be the only short-term approach for global diabetes 
prevention.44,64,66,67 Such programmes have been imple-
mented in a few high-income and middle-income 
countries,45,68,69 but their success elsewhere requires a 
ﬁ nancially accessible primary care system that prioritises 
diabetes prevention and management and is staﬀ ed and 
resourced to support lifestyle change and improve access 
to and adherence to medication.10,43,45,64,68,70
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